MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) has successfully placed 652.188 shares to international institutional investors in Europe and North America, at a price of EUR 50.00 per share.  The issue was well covered.  The Company raised gross proceeds of approximately EUR 32.6 million raising the Company's cash balance to over EUR 100 million.  Société Générale and WestLB AG acted as joint lead managers for this transaction and were joined by Janney Montgomery Scott acting as selling agent in the USA.

 

With the capital increase, the number of issued shares will increase from 6,715,322 to 7,367,510 shares, corresponding to an increase of subscribed share capital in common stock from EUR 20,145,966 to EUR 22,102,530.

 

'Today's successful funding will assist us in the further expansion of our research antibodies business, whilst retaining financial flexibility to tap other growth opportunities for the Group,' commented Dave Lemus, Chief Financial Officer of MorphoSys AG.